Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist & Deregister Contingent Value Rights for APP Pharmaceuti...
March 07 2011 - 2:58PM
Business Wire
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ)
announced today that on March 4, 2011, it filed a Form 25 with the
NASDAQ and the United States Securities and Exchange Commission
with respect to its Contingent Value Rights (“CVRs”) listed on the
NASDAQ Capital Market. As previously disclosed in its 10-K filing
on February 23, 2011, the Form 25 will delist the CVRs from the
NASDAQ and deregister the CVRs under Section 12(b) of the
Securities and Exchange Act of 1934 (the “Exchange Act”). The
NASDAQ suspended trading of the CVRs effective the close of trading
on March 4, 2011. On or about March 15, 2011, the Company intends
to suspend its reporting requirements under the Exchange Act
pending deregistration of the CVRs.
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical
company that develops, manufactures and markets injectable
pharmaceutical products with a primary focus on the oncology,
anti-infective, anesthetic/analgesic and critical care markets. The
company offers one of the most comprehensive product portfolios
used in hospitals, long-term care facilities, alternate care sites
and clinics within North America and manufactures a comprehensive
range of dosage formulations. Fresenius Kabi Pharmaceuticals
Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG,
acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more
information about APP Pharmaceuticals, Inc., please visit the
company’s Web site at www.APPpharma.com.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical
nutrition in Europe and in its most important countries of Latin
America and Asia Pacific. Fresenius Kabi’s core product range
includes infusion solutions, blood volume substitutes, I.V. drugs
and parenteral nutrition, as well as products for enteral
nutrition. Furthermore, the company provides concepts for
ambulatory health care and is focused on managing and providing
home therapies. With the philosophy “caring for life” and a
comprehensive product portfolio, the company aims at improving the
quality of life of critically and chronically ill patients all over
the world. In 2010, Fresenius Kabi achieved sales of EUR 3,672
million and an operating profit of EUR 737 million. For more
information visit the company’s Web site at www.fresenius-kabi.com.
Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co.
KGaA.
Forward-Looking Statements
The statements contained in this news release that are not
purely historical are forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this news release include statements
regarding our expectations, beliefs, hopes, goals, intentions,
initiatives or strategies, including statements regarding the
demand, supply and distribution of our products. Because these
forward-looking statements involve risks and uncertainties, there
are important factors that could cause actual results to differ
materially from those in the forward-looking statements. Additional
relevant information concerning risks are discussed under the
headings “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” in the Fresenius
Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending
December 31, 2010 and other documents the company has filed with
the Securities and Exchange Commission.
The information contained in this news release is as of the date
of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does
not assume any obligation to update or revise these forward-looking
statements to conform the statement to actual results, new
information, developments or changes in the Company’s
expectations.
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
From Apr 2024 to May 2024
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
From May 2023 to May 2024